by Nick Paul Taylor |in FierceBiotech on Apr 19, 2017 The European Commission has again sought to extinguish the United Kingdom’s lingering hopes of keeping the European Medicines Agency (EMA) in London after Brexit. Lead Brexiteer David Davis became the latest politician to claim London could retain the regulator earlier this week, only for a […]
by Nick Paul Taylor on Mar 30, 2017 in FierceBiotech Germany’s healthcare cost watchdog is continuing to push back against the European Medicines Agency’s (EMA) plans to accelerate the approval of new medicines. The German institute worries fast-track drug approvals based on limited clinical trial data or real-world evidence will become the norm—and that this […]
There is a lot of talk in industry, among the public, or among payers about VALUE related to health services or products. But do they mean the same, when they talk about it. Read a recent (March 2015) assay by Ed Schoonveld in ‘PharmExec.com’ : http://www.pharmexec.com/can-payers-and-drug-industry-agree-real-value?
Sun Pharma (India) plant was banned by the FDA for manufacturing issues March 13, 2014 | By Eric Palmer in FiercePharma A Sun Pharma plant has joined the growing ranks of Indian operations banned by the FDA for manufacturing issues. Unlike Ranbaxy Laboratories and Wockhardt, two other Indian generics players that have recently felt the […]